A B S T R A CT The effects of both synthetic and biologically produced angiotensin II (AII) upon the process of glomerular filtration were examined in the plasma-expanded (2.5% body wt) Munich-Wistar rat, by micropuncture evaluation of pressures, nephron plasma flow (rpf) and filtration rate (sngfr). Plasma expansion was chosen as a control condition because (a) response to AII was uniform and predictable, (b) endogenous generation of AII was presumably suppressed, and (c) the high control values for rpf permitted accurate determination of values for the glomerular permeability coefficient (LPA) before and during AII infusion. With subpressor quantities of synthetic Asn-1, Val-5 AII (< 5 ng/100 g body wt/min), sngfr fell from 47.7 in the control group to 39.8 nl/min/g kidney (P < 0.005). The rpf fell to 60% of control values (P < 0.001). Measurement of glomerular capillary (Pa) and Bowman's space (P.) hydrostatic pressures in surface glomeruli with a servo-nulling device permitted evaluation of the hydrostatic pressure gradient (AP = Pa-P0). AP increased from 38.1+±1.2 in control to 45.9±1.3 mm Hg after Asn-1, Val-5 AII and essentially neutralized the effect of decreased rpf in sngfr. The sngfr then fell as a result of a decrease in LPA from 0.063+0.008 in control to 0.028±0.004 nl/s/g kidney/mm Hg after Asn-1, Val-5 AII (P < 0.02).
INTRODUCTION
Angiotensin II (AII)1 has been demonstrated to be the most potent biologically produced vasoconstrictor (1) (2) (3) . ' Abbreviations used in this paper: A, glomerular capillary surface area; A, afferent arteriolar; AII, angiotensin II; AR, afferent arteriolar resistance (10' dyn s cm'); CA, Studies have demonstrated that the polypeptide acts on smooth muscle to increase vascular resistance in both the peripheral and renal circulation (4) (5) (6) . Physiologic studies have suggested that AII acts upon smooth muscle of both the afferent, precapillary arteriole and the postcapillary, efferent arteriole (5, 6) . AII has also been shown to release aldosterone from the adrenal cortex (7) , and recent studies have suggested that this action of AII may be mediated through an entirely different receptor cell for AII (8) . Therefore, the biologic activity of AIl, has been well defined for both vascular smooth muscle and the adrenal cortex in prior studies. Hornych et al. have recently demonstrated that both pressor and subpressor quantities of Asn-1, Val-5 AII produced significant constriction of glomerular capillaries of the rat, as evaluated by scanning microscopy (9) . Also, investigations by Sraer et al., utilizing isolated glomeruli, have shown a reduction in glomerular diameter when glomeruli were suspended in solutions containing Asn-1, Val-5 AII (10) . These studies suggest an action for AII on the glomerular capillary, a portion of the vasculature that does not possess smooth muscle.
Although the potential AII effect on the glomerular capillary may not contribute significantly to the overall effect of All upon renal vascular resistance, a reduction in capillary radius should be associated with a proportional decrease in glomerular capillary surface area (A).
The purposes of the present study are to: (a) determine whether low doses of Asn-1, Val-5 AII provides a reduction in the glomerular permeability coefficient (LPA), either through decreases in filtering surface area (A) or through reduction in local capillary permeability (Lu) (11, 12) ; (b) determine if the AII produced endogenously by the rat (Asp-1, Ile-5 AII) (13) has effects similar to those of Asn-1, Val-5 AII; and (c) define the relative effects of both forms of AII upon peripheral vascular resistance and the glomerular permeability coefficient.
METHODS
Experiments were performed on male Munich-Wistar rats (160-240 g), bred and housed at the animal facility at the hct, hematocrit(%o); 1, capillary length; Lp, local capillary permeability; LA, total glomerular permeability (nl/s/g kidney/mm Hg); MAP, mean arterial blood pressure (mm Hg); AP, hydrostatic pressure gradient between glomerular capillary and Bowman's space (mm Hg); PG, glomerular capillary hydrostatic pressure (mm Hg); Pt, Bowman's space or proximal tubule hydrostatic pressure (mm Hg); 7r, oncotic pressure (mm Hg); rbf, nephron blood flow (nl/ min/g kidney); rpf, nephron plasma flow (nl/min/g kidney); RPF, kidney plasma flow (ml/min/g kidney); snff, nephron filtration fraction (sngfr/rpf); sngfr, superficial nephron filtration rate (nl/min/g kidney); x*, glomerular capillary length.
San Diego Veterans Administration Hospital, La Jolla, Calif. Rats were fed regular chow (Ralston Purina Co., St. Louis, Mo.) until approximately 16 h before micropuncture surgery, and permitted free access to water. Animals were anesthetized with Inactin (100 mg/kg body wt, i.p., Promonta, Hamburg, W. Germany) and a tracheostomy (P.E. 240) was immediately performed, followed by catheter (P.E. 50) placement in left jugular vein, left femoral artery, and bladder. The rat was then turned onto the right side on a servo-controlled, heated animal table, a left subcostal incision was made, and the kidney was exposed, placed into a Lucite cup, and lined as previously described (11, 12, 14) . A ureteral catheter (P.E. 50) about 3 cm long was utilized to collect urine from the left kidney. Surgical losses were not replaced but an infusion of isotonic NaCl-NaHCOs was maintained at 0.5%o body wt/h until volume expansion was undertaken.
On the morning of the study a litter mate was sacrificed as a plasma donor. All rats were infused with 2.5%o (body wt) of donor plasma over a total of 60 min. At this time, an infusion of [14C] inulin (-40 juCi/ml) was infused continuously at 0.5% body wt/h. At the end of this infusion, urine flow rate was measured and an infusion of isotonic NaCl-NaHCO3 was begun to equal this volume flow rate to maintain both the degree of volume expansion and a constant systemic protein concentration during all measurements.
Two general types of studies were performed: a large number of unpaired studies in four groups after plasma volume expansion; (a) control, (b) subpressor doses of Asn-1,Val-5 AII, (c) low-dose rat Asp-1,Ile-5 AII, and (d) high-dose AII; and paired studies in which endogenous rat AII was infused after measurements in a control plasmaexpanded condition. The unpaired studies were found preferable because the degree of expansion and time after expansion was uniform at the time of AII infusion. With time and lesser degrees of expansion, intrarenal AII generation may increase the variability of response and increase the variance of observations. The paired studies were performed to confirm the effects of AII on the filtration process. After volume expansion in unpaired group studies, angiotensin infusion was begun and the rate rapidly increased to the stable, desired value while systemic blood pressure was constantly monitored. A separate intravenous infusion rate was again adjusted to urine output after a stable, constant angiotensin infusion was established. Since approximately 10-15 min were required to achieve the desired angiotensin infusion rate, a similar period of time was allowed in control plasma expansion before initial measurements.
Experimental groups. Studies were performed on four groups of animals, all of which were expanded with isoncotic plasma (2.5%o body wt). Prior volume expansion elevates nephron plasma flow to more than twice the normal hydropenic value and thereby disequilibrates the effective filtration pressure, and a positive value persists at the efferent end of the glomierular capillary (15) . This condition permits calculation of an accurate and unique value for the glomerular permeability coefficient (LA) (11, 12) . If filtration pressure equilibrium persists, as in the normal hydropenic rat, only a minimum possible value for LpA may be defined (11, 12, 14) . The control group (n= 11) consisted of plasma-expanded rats. The second group (n= 6) consisted of similarly expanded rats during the infusion of subpressor quantities (< 10 mm Hg increase) of Asn-1, Val-5 AII (Ciba Pharmaceutical Company, Summit, N. J.) (< 5 ng/100 g body wt/min). The third group of rats 420 R. C. Blantz, K. S. Konnen, and B. J. Tucker (n = 5) was also plasma expanded and studied during low-dose infusions of Asp-i, Ile-5 AII (< 3 ng/100 g body wt/min), the form of AII produced endogenously by the rat (13) . In this group, the infusion rate of Asn-1, Val-5 AII could not be duplicated without significant systemic hypertension. In fact, increases in blood pressure occurred consistently with an infusion rate as low as 1-2 ng/100 g body wt/min. The relative potency of the endogenous AII and the synthesized AII (Asn-1, Val-5 AII) was quite similar to that previously reported (16) . The last group (n =6) involved a duplication of the Asn-1, Val-5 AII infusion rate with the endogenously produced AII (Asp-i, Ile-5 AII), again upon the background of isoncotic plasma expansion. At infusion rates of > 5 ng/100 g body wt/min, the effects were uniformly hypertensive in the expanded rat.
Paired studies. In these studies the rats were expanded as in other groups and all measurements obtained. At the end of the control period, an infusion of Asp-i, Ile-5 AII was begun to produce an elevation of systemic blood pressure of at least 25 mm Hg. The infusion rate was then continued at this level. A period of 15 min then elapsed at a stable, elevated blood pressure before experimental measurements were begun. All micropuncture and clearance measurements were then repeated during this stable AII infusion.
Micropuncture measurements. After stabilization of urine flow and intravenous infusion rate in each group, several measurements were obtained in each animal over a maximum of 80-90 min. Pressures were measured in all accessible glomerular capillaries and the accompanying Bowman's space with a servo-nulling device with 1-jsm-tip pipettes. Pressures were also measured in several proximal tubules and in a set of "star" efferent peritubular capillaries. The specific operation of this device and the procedures and criteria required for adequate pressure measurements in glomerular capillaries have been explained in detail in previous publications from this laboratory (11, 12, 17 During the entire period of measurements, the total urine volume was collected in preweighed containers under oil and from the radioactivity in both urine and plasma samples, the total kidney glomerular filtration rate (GFR) was determined (11, 12, 14) . Usually, two separate collection periods were obtained from both right and left kidneys. At the end of the measurements, a renal vein blood sample was obtained with a heparinized 25-35-jim-tip glass pipette to determine the rate of total renal plasma flow from the extraction of ["4C] inulin. After completion of each study, the left kidney was removed and weighed.
I
In paired studies, the complete sequence of measurements was performed both during the control period and during the AII infusion.
Analytical methods. Nephron filtration rate was calculated from the total counts of ["C]inulin in the tubular fluid sample divided by the plasma counts per nanoliter and the time of collection. Total GFR kidney plasma flow and filtration fraction were calculated as previously described (11, 12, 14) .
After collection of efferent peritubular blood samples, the tips were sealed with several coats of Eastman 910 (Eastman Kodak Co., Rochester, N. Y.) and the cells separated from plasma by centrifugation. At least three 7-nl samples were obtained from each collection with a constant-volume quartz pipette. Protein concentration was determined from a micro-adaptation of the Lowry protein method (18), as described in prior communications from this laboratory (12, 14) . Each sample was read in triplicate and therefore the efferent peritubular protein concentrations were usually determined from nine readings.
Plasma and urine electrolytes were determined on a flame photometer (Instrumentation Laboratory, Inc., Lexington, Mass. EFP,* = (AlP -).* where xr = oncotic pressure (mm Hg) which is related to C (g/100 ml) as follows: Vr=1.76 C +0.28 C' (11, 12, 14) a simplification of the empirical relationship described by Landis and Pappenheimer (20) .
7r=2.1 C +0.16 C2+0.009 C8 The EFP is defined as follows:
The EFP,* curve and LA are determined by an iterative method as described previously from this laboratory (12) .
Statistical methods. All input variables were submitted to analysis of variance (21) and variance estimates of all variables were carried through the calculation of EFP, generation of the EFP,* profile, and LA to define the final estimate of variance of these values (12) . The values for LA after Asn-1, Val-5 All and high-dose Asp-1, Ile-5 All were applied to both the normal hydropenic values for AP, rpf, and CA and the predicted changes in these values after AII, based upon percentage changes observed in the plasma volume expanded condition. Also, the LA value in the control conditions was applied to the post-AII condition (with AII values for AlP, rpf, and CA) to predict the EFP,* profile if LA had not been altered by All (Fig. 3) .
RESULTS
Group data. The data obtained in the three experimental groups will be compared to the control plasma volume expansion (2.5% body wt) with no infusion of AII. As stated, all animals were expanded identically and total intravenous infusion rates were adjusted to equal spontaneous urine output.
Effects of Asn-1, Val-5 All infusion (<5 ng/100 g body wt/min). In no case did blood pressure (MAP) increase by more than 10 mm Hg (122+3 versus 133±6, P > 0.05 after AII). The AII infusion rate was established at the first sign of an elevation in MAP. The sngfr was 47.7±1.4 nl/min g kidney (n = 50) in the control plasma expansion group, and in the experimental group was significantly lower during Asn-1, Val-5 AII infusion at 39.8+2.2 nl/min/g kidney (n = 29) (P < 0.005) ( Figs. 1 and 2 ). The nephron plasma flow (rpf) was also significantly lower during AII infusion, at 119±7 nl/min/g kidney, compared to 200+9 in the control group (P < 0.001) (Fig. 1) . rbf fell from 346+ 16 to 214±12 nl/min/g kidney (P<0.001).
Data were also analyzed by animal mean values: the sngfr was 47.3±2.4 (n = 11) in control rats and 39.6+ 4.0 (n = 6) nl/min/g kidney (0.1 > P > 0.05) after Asn-1, Val-5 AII, the rpf was 198±18 in controls and 119±+14 nl/min/g kidney (P < 0.005) after AII, and the rbf was 344±32 in control rats and 213±25 nl/ min/g kidney (P <0.01) after AI. This reduction in rbf was the result of an increase in both afferent (AR) and efferent arteriolar resistance (ER). AR rose to 26±3 X 10' dyn s cm ' with AII, compared to 17±2 X 10' dyn s cm' in the control state (P > 0.02). The increase in ER was more impressive at 10±1 X 10' dyn s cm' in control rats and 23+3 X 10' during Asn-1, Val-5 AII infusion (P <0.001). Although the control conditions differed, the respective changes in AR and ER were quite similar to those reported for the hydropenic Munich-Wistar rat in a recent abstract by Deen et al. (22) .
The P0 rose with AI, presumably as a result of the greater increase in ER. Control Pa was 59.5±+1.5 mm Hg and 64.0±0.8 mm Hg during AII infusion (P < 0.02). In contrast to other conditions in which Pa rises (11, 14, 16) , the proximal tubule hydrostatic pressure (Pt) fell with AII infusion from 20.3±0.7 in control to 18.4+ 0.6 mm Hg (P < 0.05). The net effect of the divergent changes in Pa and Pt was a rather dramatic increase in hydrostatic pressure gradient between glomerular capillary and Bowman's space (AP) from a control group value of 38.1±+1.2 mm Hg (n = 25) to 45.9± 1.3 (n = 12) during AII infusion (P <0.001) ( Table I .
Total kidney GFR was 1.50±0.20 ml/min/g kidney in the control group (n = 6) and 1.10±0.08 during AII infusion (0.2 > P > 0.1). Renal plasma flow was 3.15+ 0.7 ml/min/g kidney and renal blood flow 5.7±+1.2 ml/ min/g kidney (n = 5) in this group. Total filtration fraction was 0.38±0.04, very similar to the snff (0.34±0.03).
The appearance of the kidney surface was not greatly altered by the infusion of Asn-1, Val-5 AI. The only consistent changes were a slight diminution in tubular diameter accompanied by an appearance of increasing "thickness" of tubular cells or wall opacity and some decrease in the "tightness" of the renal capsule. The general color and relationship of tubular and vascular structures were not changed by AII infusion.
The systemic oncotic pressure was somewhat lower 28 .4±0.8 mm Hg in the control condition (P > 0.5). The snff was therefore 0.25+0.02 in the control condition, but significantly higher during the AII infusion at 0.34±0.03 (P < 0.02). As a result of the high control rpf, the EFP at the end of the glomerular capillary (EFPs = AP -rB) was greater than 0 at 9.5± 1.7 mm Hg. During AII infusion the mean EFPz was higher at 16.0±+1.3 mm Hg (P < 0.001) in spite of the large reduction in rpf with AI. The only other factor which could have further disequilibrated the EFP while rpf fell was a large reduction in LPA (14, 16a) . The effect of the reduction in rpf upon sngfr was effectively neutralized by the large rise in AP. Therefore, the fall in sngfr observed must primarily result from a decrease in LPA.
The profile of EFP.* was generated for the control condition and during Asn-1, Val-5 AII infusion. The EFP in the control group was 14.5±1.6 mm Hg and was significantly higher during AII infusion, at 23.5+0.8 mm Hg (P <0.005). Since sngfr fell while EFP rose, the LPA must have decreased with Asn-1, Val-5 All in subpressor quantities. LPA in the control group was 0.063+ 0.008 nl/s/g kidney mm Hg (n = 11) and was signifi- cantly lower in this AII group at 0.028±0.004 nl/s/g kidney mm Hg (n = 6) (P < 0.02) (Fig. 2) . If LPA had remained equal to control values after Asn-1, Val-5 AII, the sngfr would not have changed from control values. Also, the profile of EFPw* would have differed and EFP remained relatively constant, equal to the control value. In Fig. 3 , the observed profile of EFP along x* during AII is shown, along with the EFP profile which would obtain if LPA had remained equal to the value in control animals. The figure demonstrates that the reduction in LPA alters the profile of EFPx* and increases EFP by reducing the rate of ultrafiltration along x* and decreasing the rate of rise in r along the capillary.
All of the effects in this group occurred before evidence of significant increases in peripheral resistance, as indicated by no change in MAP. The AII effects were the result of infusion of a form of the peptide not produced biologically in any species (23) . Although the qualitative effects of Asn-1, Val-5 AII have been reported identical to endogenously produced AII (24, 25) , it remains possible that these results were unique to this synthetic form of AI. For these reasons, studies were performed with Asp-1, Ile-5 AII, the form of AII produced by the rat (13).
Effects of low-dose Asp-1, fle-S AIl (< 3 ng/100 g body wt/min). Initially, we attempted to duplicate the Angiotensin II Effects upon the Glomerulus of the Rat protocol of the Asn-1, Val-5 AII group, in that subpressor quantities of Asp-i, Ile-5 AII were attempted. Because of the greater potency of this form of AII, sudden rises in MAP were the rule, even if the infusion rates were gradually increased. As a result, MAP was significantly higher than control at 146±4 mm Hg (P < 0.001), although the maximum rate of infusion was 2.5 ng/100 g body wt/min in one rat and lower in the others. The sngfr in this low-dose Asp-i, Ile-5 AII group was not different from the control value at 50.4±2.5 (P > 0.3) ( Table II) . The Pt was 17.4+0.6 mm Hg, significantly lower than control values (P <0.01) as was the HPu (18.9±1.1, P < 0.05). None of the factors that determine sngfr was altered from the control group values, although there was a trend towards a higher AP at 43.2±2.6 mm Hg (P > 0.05) (Fig. 1) . The rpf was 233±25 (P > 0.2) and rbf 427+48 nl/min/g kidney (P > 0.10) during the low-dose native AII infusion (Fig. 1) . As reflected by the larger standard error for rpf and rbf in this group, there was a greater variability among animals in the response to low-dose AI. When data were analyzed from animal mean values there were also no significant differences in sngfr or determinants of filtration. AR and ER were nearly identical to the 424 R. C. Blantz, K. S. Konnen, and B. J. Tucker (n = 50) (n = 11) (n = 11) (n = 25) (n = 11) (n = 11) (n = 11) (n = 11) (n = 11) control values (P > 0.8). The snff was also nearly identical to the control value at 0.23±0.04 (P > 0.60).
All data are shown in Table II . Both VrA and 7re were unchanged, but hematocrit was significantly higher at 45±2 (P < 0.05).
GFR in this group was 1.47±0.1 (n = 6), very similar to the control group value (1.50+0.20 ml/min/g kidney, P > 0.90). Renal plasma flow was 4.1±0.5 nl/min/g kidney and renal blood flow 7.6+0.9 nl/min/g kidney (n = 3).
Although sngfr was unchanged from the control group, the EFP3 tended to be higher, 14.5+2.1 mm Hg compared to 9.5±1.7 mm Hg, but did not achieve statistical significance (0.1 > P > 0.05). The EFP was also numerically higher at 19.5+1.9 mm Hg but also not significantly (0.1 > P> 0.05). Similarly, the LpA was 0.044+0.007 nl/s/g kidney mm Hg compared to 0.063+ 0.008 in control (0.20 > P > 0.10). In summary, minimum pressor quantities of Asp-1, Ile-5 AII produce no alterations in either sngfr or factors that determine sngfr. There was a tendency towards a lower LPA and higher EFP. In spite of significant peripheral vasoconstrictor effect as evidenced by increased MAP, there was no significant effect on either renal vascular resistances or LPA.
Effects of high-dose Asp-1, fle-S All. The lack of significant effect of this form of AII in lower doses may have resulted solely from the reduced quantity of AII delivered to the kidney. We have therefore infused at least 5 ng/100 g body wt/min of the native AII to duplicate the quantities of Asn-1, Val-5 AII infused (subpressor dose). It was recognized that this infusion rate would consistently produce systemic hypertension. The MAP was 143±4 mm Hg, significantly higher than control (122±3 mm Hg, P < 0.001), but in spite of the greater infusion rate, not different from the lower dose group. The sngfr was reduced to 34.0+2.3 nl/min/g kidney with the higher dose of native AII, a value similar to that in the Asn-1, Val-5 AII group after similar quantities of AI. All factors measured are shown in Table III , and the values are strikingly similar to the values obtained when Asn-1, Val-5 AII was administered in similar quantities. Both the AR and ER increased to 38±6 X 10' (P < 0.005) and 27±4 X 109 dyn s cm' (P < 0.001) respectively, and, as a result, rpf fell to 99.3±6.5 nl/min/g kidney (P < 0.001) and rbf to 182±+14 nl/min/g kidney (P <0.001) (Fig. 1 UNaV was 5.5±1.7 ueq/min (P > 0.1) and FEN. 3.1±
1.4% (P > 0.3) in the higher-dose Asp-1, Ile-5 AII group. Urinary potassium excretion (UKV) was also unaltered by AII infusion.
In Fig. 4 , the association of changes in afferent and efferent resistances with the changes in LPA is demonstrated. The correlation was rather striking where high resistances at both afferent and efferent arterioles were associated with lower values for LPA in the 5 ng/100 g body wt/ min AII groups.
Paired studies on the effect of Asp-1, fle-S AIL. ±-0.008* ±1.7 (n = 50) (n = 11) (n = 11) (n = 25) (n = 11) (n = 11) (n = 11) (n = 11) (n = 11) ±-0.004 ±;2.5 (n = 27) (n = 6) (n = 6) (n = 19) (n = 6) (n = 6) (n = 6) (n = 6) (n = 6) the control state and 46±1% during AII infusion (P > 0.8). Therefore both unpaired and paired studies have revealed that AI, when infused in sufficient but modest quantities, produces a dramatic reduction in LiA. DISCUSSION Utilizing both synthetic and endogenously produced forms of AII (13), we have demonstrated an effect of this hormone upon nephron filtration rate, nephron plasma flow, the hydrostatic pressure gradient, and the glomerular permeability coefficient in both paired and group studies. The specific role of AII in volume homeostasis has been related to the capacity to regulate aldosterone release (7, 26) and has been proposed to regulate the rate of glomerular filtration through its intrarenal release via tubulo-glomerular feedback (27) (28) (29) (30) (31) (32) (33) (34) . Specific quantitative observations on the effects of AII on the glomerular permeability coefficient have not been previously described, although previous studies have speculated that AII might reduce glomerular capillary radius (9, 10) . This effect might be mediated by activation of contractile properties of the mesangial cell (35) . Studies have also permitted some insights into the relative peripheral and glomerular effects of the two forms of AI.
The effects of All on glomerular filtration dynamics were examined on a background of isoncotic plasma volume expansion. Prior plasma volume expansion affords certain advantages in the analysis of the effects of these agents on the filtration process. Firstly, the vascular resistance was low in the control condition and was therefore quite predictably responsive to vasoconstrictor agents. Secondly, prior volume expansion should have suppressed the renin system and prevented endogenous angiotensin generation. Thirdly, the high control renal plasma flow produced disequilibration of the effective filtration pressure in the control condition, which permitted determination of an accurate and unique value for glomerular permeability coefficient (LpA) (16a (11, 12, 14 Under the conditions of control plasma expansion, a discrete value for LPA could be defined and was 0.063 and 0.061 nl/s/g kidney mm Hg, significantly different from the value we have defined under disequilibrated conditions after hyperoncotic albumin expansion at somewhat higher values for both systemic oncotic pressure and nephron plasma flow (11) .
After the infusion of approximately 5 ng/100 g body wt/min of Asn-1, Val-5 AII (subpressor quantities) and Asp-1, Ile-5 AII (pressor quantities) in group studies, the nephron plasma flow fell to 40-60% of control values. As an isolated event, this reduction should have decreased the efferent effective filtration pressure to a value approaching filtration pressure equilibrium (Fig. 3) (23) . Studies with Asp-1, Ile-5 AII revealed that lesser quantities of this compound were required to produce hypertension as a result of peripheral vasoconstriction. In the low-dose group, 2.5 ng/100 g body wt/min was the maximum amount of this agent infused, approximately one-half the dose of Asn-1, Val-5 AII used. Therefore, this agent appears more potent per nanogram as a peripheral vasoconstrictor (16) , but with minimum pressor doses has little effect on both the glomerular capillary and afferent and efferent resistances.
Although similar total doses of both forms of AII were required to obtain a reduction in LPA, the endogenously produced AII had a greater peripheral vascular effect than the nonbiologically synthesized preparation. This greater effect has been previously observed and attributed to more efficient degradation of this form of AII by tissue aminopeptidases as a result of the differing NH2-terminal amino acid substitution (37) . However, since the glomerular capillary effects were nearly identical at the same dose of both agents, the kinetics of AII action and degradation must be similar in this vascular bed. The Asn-1, Val-5 AII compound produced a reduction in nephron plasma flow and increase in vascular resistance while there was no evidence of significant effect upon peripheral vessels, as evidenced by the lack of a significantly increased systemic blood pressure.
The major finding of this study is the reduction in LPA with AI. Recent studies have suggested at least quantitative if not qualitative differences in the adrenal cortical and peripheral effects of AII (8, 38) , although possibly mediated by AII action upon contractile cells. Since no smooth muscle cells are located in or around the glomerular capillary (35, 39) , a separate effector cell that reduces either local permeability or effective surface area must be postulated. No direct evidence has been provided that elucidates either the effector cell or the specific mechanism for the AII-mediated reduction in gomerular permeability coefficient. Either a reduction in local permeability of the glomerular membrane or a decrease in capillary surface area or both could explain the lower LPA.
If all of the decrease in LPA was a result of reduced radius, the changes would be directly proportional (A = 27rrl). Measurements of capillary pressure in the same glomerulus performed in this laboratory have suggested that the decrement in PG along the length of the glomerular capillary (APG) is at most 1-2 mm Hg in the hydropenic state. If the observed decrease in LpA were entirely due to reduced capillary radius, then, utilizing Poiseuillian relationships, the APG should have increased considerably to 16-32 mm Hg. This change should have resulted in a marked increase in variance in PG after AII; however, no such increase was observed in this study. It is recognized that these estimates are only approximations of the real physiologic events and are therefore subject to inaccuracies. It remains quite likely that the observed reductions in LPA may have been mediated, at least partially, by decreases in local capillary permeability (Lp). That changes in LPA correlated positively with increased renal vascular resistance (Fig. 4) suggests only that the effect of AII upon renal vascular smooth muscle coincided with the effect on LPA. Even if the LPA effects were due to reduced capillary radius alone, the increased resistance would not contribute significantly to the increase in total renal vascular resistance (10-12% of total) due to the very low control capillary resistance.
The biologic relevance of the present findings remains somewhat ill-defined. Certainly the demonstration of an AII effect on LpA may be added to the known effects on vascular smooth muscle and aldosterone release from the adrenal. However, have the effective biologic levels of AII been achieved in the present study? It has been possible to delineate the specific range of values for interstitial AII concentration from the evaluation of renal lymph AII levels by radioimmunoassay (40) . The AII levels after aortic constriction were well above the intravascular concentration produced by the infusion of 5 ng/100 g body wt/min of AI. It is therefore possible that much higher levels of endogenously generated AII may be achieved at the effector site for LPA reduction under conditions of maximum AII generation.
We have evaluated the change in LPA under conditions of high nephron plasma flow during plasma expansion because accurate calculations can be performed without attainment of filtration pressure equilibrium. In the hydropenic condition, at filtration pressure equilibrium, the effect of this quantitative reduction in LPA upon sngfr would be diminished, due to both the corresponding decrease in nephron plasma flow and increased AP. At filtration pressure equilibrium, if proportional reductions in plasma flow are similar, the dominant factor acting to reduce sngfr should be the reduction in plasma flow. The reduction in LPA would contribute to a reduction in sngfr if LPA fell to -0.02 nl/s/g kidney/mm Hg and AP and nephron plasma flow changed in similar proportions to those observed in the plasma-expanded state. It must be assumed that the much higher potential interstitial AII concentrations generated endogenously could affect larger LpA reductions.
One cannot directly apply the results obtained after the intravenous infusion of AII to the question of a potential intrarenal role for this substance. Preceding studies have provided indirect evidence that the mesangial cell might provide the site of AII receptor and the effector cell mediating the reduction in LPA (9, 10 (31, 47) . Alteration in hydrostatic pressures in the glomerular capillary has proven inadequate as a single mechanism explaining the efferent limb of this tubulo-glomerular feedback system (7, 33) . We have suggested that if such a relation exists, it must be mediated through changes in nephron plasma flow (17) . The present findings of an AII effect upon LPA raise the question whether this mechanism could explain; in part, the observed reciprocal relationship. Thurau and Schnermann, in early studies, suggested as one of several mechanisms a specific AII effect on the glomerular capillary (47) . However, we would reiterate that there are severe constraints on the expression of reduced LPA in the hydropenic rat at filtration pressure equilibrium. This statement is especially true with reductions in nephron plasma flow and increased AP. Because of the large decrease in nephron plasma flow, large reductions in LPA will be tolerated by the system and not lead to disequilibration of the effective filtration pressure. In addition, the increase in AP will substantially neutralize the effect of both decreased nephron plasma flow and LPA upon nephron filtration rate.
In summary, for reduced LPA to produce a decrease in nephron filtration rate, the LPA effects must predominate over the effects on both nephron plasma flow and AP before disequilibration of the effective filtration pressure and decrease in nephron filtration rate will result. Therefore, a specific biologic role for AII upon LPA in the modification of sngfr in the hydropenic animal remains speculative at this time. A third biologic effect for AII has been described in this study, an effect of AII upon the permeability coefficient of the glomerular capillary (LA). The effect of AII appears to be a mechanism separate and distinct from those previously described on vascular smooth muscle and upon the adrenal cortex.
